Diabetes type 2

All type of patients:  1 trials  - SUSTAIN 6

semaglutide vs placebo

cardiovascular events by 26% (fully demonstrated)

suggested nephropathy by 36% (not demonstrated)

suggested retinopathy by 76% (not demonstrated)




- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons